Episode 69: ESMO 2023 - Metastatic Breast Cancer
Michael and Josh continue their examination of the crème-de-la-crème of the European Society of Medical Oncology conference of 2023. Today they focus on metastatic breast cancer, with a particular focus on antibody-drug conjugates (ADCs). T-Dxd, Dato-Dxd and trastuzumab duocarmazine are just three of the many novel agents in this space, and likely represent part of the future (and the present) of medical oncology. How effective are these treatments? Will the final results of the TULIP study blossom like its namesake? Will T-Dxd fulfil its DESTINY and become a treatment option for HER-2 low advanced breast cancer? Will Dato-Dxd assist in making cancer BEGON(IA)? For more excellent puns and the answers to these questions and more, listen on!
Studies discussed in this episode. Subscription may be required
Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637914
Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637972
Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637983
First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637984
